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In  this  study,  a preparation  of  saponins  (QB-90U)  extracted  from  leaves  of  Quillaja  brasiliensis  collected
in  Uruguay  was  evaluated  as  a  vaccine  adjuvant  by  comparison  with  alum  and the  well  known  saponin-
based  adjuvant,  Quil  A.  The  haemolytic  activity  and  cellular  toxicity  of  the  saponin  preparations  were
also  evaluated.  QB-90U  was  only  slightly  haemolytic  and  showed  a low  cytotoxicity  when  compared
to  Quil  A.  The  adjuvant  properties  of QB-90U  were  assayed  by sub-cutaneous  immunization  of  mice
with  a  preparation  of  inactivated  bovine  herpesvirus  5  (BoHV-5)  either  with  no  adjuvant  or  adjuvanted
with  QB-90U,  Quil A  or  alum.  Serum  levels  of anti-BoHV-5  IgG,  IgG1,  IgG2a,  IgG2b  and  also  IgG3  were
signiﬁcantly  increased  by QB-90U  and  were  of  the  same  order  as  those  elicited  by Quil  A.  Furthermore,
high  titres  of neutralizing  antibodies  were  found  to be present  in the serum  of  immunized  animals  fromow  toxicity
umoral and cell responses
oHV-5
irus  vaccine
both  groups.  The  cellular  response  induced  by QB-90U  did  also  reproduce  the  one elicited  by  Quil  A.  In
fact,  a robust  DTH  response  was  observed  in mice  immunized  with  both  saponin  preparations;  as  well
as  increased  splenocytes  levels  of  Th1-type  cytokines,  namely  IFN-  and  IL-2.  Taken  together,  the  above
results  conﬁrm  and  extend  our  previous  observation  regarding  the similarity  of  the  responses  elicited
by  Quil  A  and  the  saponin  preparation  from  Q. brasiliensis  (Fleck  et al.,  2006)  and  indicate  that  QB-90U  is
worth  of  further  studies  as  a safe  and  potent  vaccine  adjuvant.. Introduction
Alum is the most widely employed adjuvant in human vaccine
ormulations [1]. It appears to induce a local pro-inﬂammatory
eaction leading to a T helper 2 (Th2) type response [2] with
nhanced production of antibodies to co-administered antigens [3].
he small number of other currently approved vaccine adjuvants
or human use does not usually elicit the desired protective, sus-
ained immune responses. In addition, alum is a poor inducer of
ell-mediated immunity [4], which contributes to the elimination
f virus and other intracellular pathogens as well as cancer cells.
hus, there is a broadly recognized need for the development of
ew adjuvants [5,6].
∗ Corresponding author. Tel.: +598 2 4871288 ext 1124; fax: +598 2 4873073.
E-mail  address: ff@fq.edu.uy (F. Ferreira).
264-410X ©  2011 Elsevier Ltd. 
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Open access under the Elsevier OA license.© 2011 Elsevier Ltd   . 
In this context, the adjuvant potential of natural products and of
saponins in particular, has been largely explored. Saponins are nat-
ural steroidal or triterpenic glycosides with many biological and
pharmacological activities, including potential adjuvant proper-
ties [7,8]. Actually, triterpenoid saponins extracted from Quillaja
saponaria Molina have a long usage record as adjuvants in veteri-
nary vaccines [9]. In some cases, saponins may  show an alum-type
adjuvant effect [10], but they have been mostly studied for their
capacity to stimulate cell-mediated immunity. A partially puri-
ﬁed mixture of saponins from Q. saponaria, called Quil A [11], is
the most widely used and studied saponin-based vaccine adju-
vant. It is known to stimulate both humoral and cellular responses
against co-administered antigens, with the generation of T helper
1 (Th1) and cytotoxic cells (CTLs) responses. The ability to elicit
Open access under the Elsevier OA license.this type of immune response makes them ideal for use in vac-
cines directed against intracellular pathogens, virus, as well as in
therapeutic cancer vaccines [7,12]. However, in spite of its rec-
ognized adjuvant potential, the use of Quil A in human vaccines
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as been restricted due to undesirable side effects, including local
eactions, haemolytic activity and even systemic toxicity [7,11].
he haemolytic activity of saponins has been shown to be closely
elated to their structure, both the aglycone type and the oligosac-
haride residues [13,14] and, for this reason, considerable efforts
ave been undertaken over the last decades for the discovery of
ew plant saponins with improved adjuvant activity and reduced
oxicity [7,9,15].
Quillaja brasiliensis (A. St.-Hil. et Tul.) Mart. is a tree native to
outhern Brazil and Uruguay. It is commonly known as “soap tree”
n view of the capacity of its leaves and bark to produce abun-
ant foam in water due to their high saponin content. Some of us
ave been involved in the chemical characterization of the saponins
resent in the leaves of Q. brasiliensis [16] and, in particular, in one
aponin fraction, named QB-90, which was found to have similar-
ties with Quil A [17]. Furthermore, we have shown that QB-90
resents low toxicity when subcutaneously administered to mice
nd that it strongly potentiates the immune response to a viral
ntigen (bovine herpesvirus type 1, BoHV-1) [17].
In  this work, we contribute to improve the knowledge of the
djuvant activity of the saponins fraction named QB-90U prepared
rom leaves of Q. brasiliensis collected in Uruguay, in comparison
o two of the most commonly used adjuvants (alum and Quil A).
e analyze the haemolytic activity and cytotoxicity of QB-90U and
valuate its potential as vaccine adjuvant using another viral anti-
en as model, by comparing its performance with those of Quil A
nd alum. For the latter purpose, we assess the antibody (IgG and
ts subclasses) and cellular (DTH assay) responses of mice immu-
ized with a preparation of inactivated BoHV-5. In addition, we
peciﬁcally evaluate whether QB-90U is capable of inducing the
eneration of Th1 CD4+ T cells by assessing the expression levels of
h1 cytokines in splenocytes from immunized mice.
.  Materials and methods
.1.  Plant material and preparation of QB-90
Q. brasiliensis (A. St.-Hil. et Tul.) Mart. leaves were collected in
arque Battle, Montevideo, Uruguay. The samples were identiﬁed
y Eduardo Alonso of the Botany Department, Facultad de Química,
delaR, and a voucher sample was kept at the Herbarium of the
aculty (MVFQ 4321).
Air-dried  powdered leaves were extracted in distilled water
1:10, w/v) under constant stirring at room temperature for 8 h.
he extract was then ﬁltered and lyophilized to obtain the aqueous
xtract from which fraction QB-90U was puriﬁed following the pro-
edure described by Fleck et al. [17]. Brieﬂy, the aqueous saponin
xtract was applied to a silica Lichroprep column and eluted with
 stepwise gradient of aqueous methanol 0–100% methanol. The
ractions were analyzed by TLC, and those with a similar saponin
omposition were pooled together to give the QB-90U fraction.
.2.  Assays of saponin toxicity
.2.1.  Haemolytic activity assay
The haemolytic activity of QB-90U and Quil A (BRENNTAG,
enmark) was assessed as described before [10], except that guinea
ig red blood cells at a 1% concentration were used for the assays.
oncentration ranges from 500 g/mL to 50 g/mL (500, 250, 230,
00, 180, 160, 150, 130, 110, 100, 70 and 50 g/mL) and from
10 g/mL to 10 g/mL (110, 100, 80, 60, 50, 30, 20, 15 and
0 g/mL) were used for QB-90U and Quil A, respectively, each
ample was tested in triplicate. Saline and Q. saponaria saponins
250 g/mL) were used as references for 0% and 100% haemolysis,
espectively. The mixture of Q. saponaria saponins was prepared by9 (2011) 9177– 9182
dialysis against distilled water from a commercial sample [10]. The
haemolytic activity was expressed as the concentration producing
50% of the maximum haemolysis (HD50).
2.2.2. Cell cytotoxicity assay
Cytotoxicity  was  determined using the MTT  assay, in general
following the original procedure [18]. Brieﬂy, VERO cells (African
Green Monkey Kidney, ATCC CCL-81) were cultured in Eagle’s min-
imal essential medium (E-MEM) supplemented with 10% foetal
bovine serum (FBS, GIBCO) and antibiotics (penicillin 100 UI/mL;
streptomycin 100 g/mL) (E-MEM/FBS). Cells were seeded at a
concentration of 4.0 × 104 per well on 96-well microplates and
maintained at 37 ◦C under a humid atmosphere with 5% CO2. After
18 h, the medium was removed and 100 L of E-MEM/FBS con-
taining different concentrations (100, 150, 200 and 300 g/mL) of
either QB-90U or Quil A were added to each well in triplicate. The
plates were incubated as above; after 48 h, 50 L of 2 mg/mL MTT
(Sigma Chemical Co., Saint Louis, MO,  USA) were added to each well
and the cells were incubated for a further 4 h. The plates were cen-
trifuged (1400 × g for 5 min) and the supernatant containing the
untransformed MTT  was  carefully removed. Ethanol (100 L/well)
was added to solubilize the formazan crystals, and the optical den-
sity (OD) was  measured in an ELISA reader (Anthos 2020) at 550 nm
with a 620 nm reference ﬁlter. The amount of formazan produced
was directly proportional to the number of living cells in culture.
Results were expressed as the percent OD of each culture in com-
parison with the OD of untreated control cells.
2.3. BoHV-5 antigen preparation
Madin  Darby Bovine Kidney cells (MDBK; originally ATCC
CCL-22) were routinely multiplied in E-MEM/FBS [19]. For virus
production, monolayers of MDBK were grown overnight in 150 cm2
ﬂasks and infected with BoHV-5 strain A663 [20,21] at a multiplicity
of infection of 0.1. When cytopathic effect was  evident in 90–100%
of the monolayers, the ﬂasks were frozen at −70 ◦C, thawed, and
the medium was  clariﬁed by low speed centrifugation. The viral
suspension was  inactivated with binary ethylenimine (BEI) as
described previously [22]. The median tissue culture infectious
doses (TCID50) before inactivation was 107.8/mL. The suspension
of inactivated virus (to which we refer as BoHV-5) was used as
antigen for adjuvant testing and for all assays except for the serum
neutralization test.
2.4.  Mouse immunization protocol
Female Rockefeller mice (5–6-weeks old) of the CF-1 breed were
purchased from the Fundac¸ ão Estadual de Produc¸ ão e Pesquisa em
Saúde (FEPPS, Porto Alegre, RS, Brazil), and acclimatized for 72 h
prior to use. Mice were maintained under controlled temperature
(22 ± 2 ◦C) and humidity with a 12/12 h light/dark cycle chow and
tap water were provided ad libitum. All the procedures were car-
ried out in strict accordance with the International Legislation on
the Use and Care of Laboratory Animals and were approved by the
University Committee for Animal Experiments.
Mice were divided into six groups, each consisting of six ani-
mals. The formulations of BoHV-5 were prepared under aseptic
conditions, ﬁltered through 0.22 m and kept at 4 ◦C until use. Ani-
mals were inoculated subcutaneously (in the hind neck) twice, on
days 1 and 14, with 150 L of BoHV-5 antigen plus 50 L saline
(no adjuvant group), or with either alum (Omega Produtos Quimi-
cos Ltda., 200 g), Quil A (50 g) or QB-90U (100 g) suspended or
dissolved in 50 L saline (alum, Quil A and QB-90U, groups, respec-
tively). Mice were bled prior to inoculations (on days 0 and 14) and
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Table 1
Primer sequences used for RT-qPCR.
Gene name Forward primer 5′–3′ Reverse primer 5′–3′ Prod. size
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Primers (see Table 1) were used at a ﬁnal concentration of 0.9 M.
The cycling conditions were 15 min  at 95 ◦C, followed by 40 cycles
at 95 ◦C for 15 s, and 60 ◦C for 1 min  during which the ﬂuorescence
data were collected. The expression level of the genes of interest
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Fig. 1. In vitro toxicity of QB-90U and Quil A. (a) Haemolytic activity expressed-Actin GCTTCTTTGCAGCTCCTTCGT 
IL-2 CCTGAGCAGGATGGAGAATTACA
INF- TCAGCAACAGCAAGGCGAAA 
 weeks after the second immunization (day 28); sera were kept
rozen until processed.
.5.  Immunoassays for antibodies
Anti-BoHV-5  IgG (total), IgG1, IgG2a, IgG2b, and IgG3 were
etermined for each serum sample by ELISA, carried out essen-
ially as previously described [10]. ELISA plates (Greiner Bio-One)
ere coated with the BoHV-5 suspension used for mouse immu-
ization diluted (1:100, v/v) in carbonate-bicarbonate buffer pH
.6 at 37 ◦C for 1 h. Plates were then washed three times with PBS
ontaining 0.05% Tween 20 (PBS-T) and blocked with BSA (1% in
BS) at 37 ◦C for 1 h. Sera (100 L of appropriate dilutions in PBS-T)
ere added in duplicates and incubated for 1 h at 37 ◦C. Subse-
uently, plates were washed three times with PBS-T. Next, 100 L
f appropriate dilutions in PBS-T of anti-mouse IgG (Sigma Chem-
cal Co.), IgG1 (Caltag Laboratories), IgG2a, IgG2b, or IgG3 (Zimed
aboratories) were added to the wells and plates were incubated
or another hour at 37 ◦C. After washing, 100 L of OPD (ortho-
henylenediamine, Sigma Chemical Co.) with H2O2 were added to
ach well, plates were incubated for 15 min  at 37 ◦C and the reac-
ions was stopped by adding 50 L/well of 1 N HCl. The OD was
easured in an ELISA plate reader (Anthos 2020) at 492 nm.  Anti-
ody titres were expressed in arbitrary units (AU) referred to a
tandard calibration curve prepared with a pool of positive sera.
gG3 titres were expressed in OD because they were much lower
han those for the other isotypes. All the samples were diluted 1/100
or the determination of IgG3 titres.
.6. Serum neutralization test
The presence of neutralizing antibodies to BoHV-5 in mouse sera
as analyzed in a virus neutralization test with the constant virus,
arying serum method, in 96-well cell culture plates, as previously
escribed [23]. The test was performed against 100 TCID50/50 L
f BoHV-5 strain A663.
.7.  Delayed type hypersensitivity (DTH) assay
Delayed type hypersensitivity responses were evaluated in
hree mice from each group on day 28 as previously described [10].
rieﬂy, mice were subcutaneously injected in one footpad of the
ind limb with 10 L of the BoHV-5 suspension used for immu-
ization. The thickness of the injected footpads was  measured 24 h
ater with a calliper. The swelling of mice from the control group
njected with saline was considered to be derived from the punc-
ure procedure (basal swelling). The BoHV-5-speciﬁc DTH response
f each animal was calculated based on the thickness of its injected
ootpad minus the average of the basal swelling.
.8. Evaluation of cytokine gene expression
Spleens were collected in RPMI 1640 (Gibco) under aseptic
onditions 120 days after the second immunization, minced and
echanically dissociated to obtain a homogeneous cell suspen-
ion. Erythrocytes were lysed with ammonium chloride (0.8%,
/v). After centrifugation (380 × g at 4 ◦C for 10 min), the cell
ellets were washed three times in RPMI and suspended inCGTCATCCATGGCGAACTG 68
CTTTCAATTCTGTGGCCTGCTTGGG 92
CCGCTTCCTGAGGCTGGAT 143
complete  medium: RPMI 1640 supplemented with 0.05 mM  2-
mercaptoethanol, 100 IU/mL penicillin, 100 g/mL streptomycin,
2 mM l-glutamine, and 10% FBS. Splenocytes (>95% viability as
assessed by trypan blue exclusion) were seeded onto microtubes
(100 L of 5 × 106 cells/mL), concanavalin A (Invitrogen, 5 g/mL
ﬁnal concentration) or RPMI 1640 plus BoHV-5 suspension were
added to a ﬁnal volume of 200 L in triplicate. The tubes were
incubated at 37 ◦C in a humid atmosphere containing 5% CO2 for
16 h, after which 0.5 mL  of Trizol (Invitrogen) were added; the
tubes were stored at −80 ◦C until use. RNA extraction was  per-
formed according to the manufacturer’s instructions. RNA quality
and quantity were assessed by spectrophotometric measurements
at 260/280 nm (Nanodrop); 1 g of total RNA was  treated with
DNAse-I (Invitrogen) and immediately subjected to cDNA synthesis
with random primers (Invitrogen) and M-MLV  reverse transcrip-
tase (Invitrogen).
Real-time PCR was  performed using the QuantiTect® SYBR®
Green PCR Kit (Qiagen) in a Rotor-Gene 6000 (Corbett), as follows.as  percent haemolysis (%haemolysis) referred to saline and Q. saponaria saponins
(250  g/mL), which were used as 0% and 100%, respectively. (b) Cytotoxicity assayed
on VERO cells; cell viability was measured 48 h after treatment with the indicated
saponin concentration. In (a) and (b), results are presented as the mean value ± S.D
(n = 3).
9180 F. Silveira et al. / Vaccine 29 (2011) 9177– 9182
F G and
d lum. T
( ith th
w
m
m
a
s
2
d
t
b
3
3
Q
5
u
r
h
h
p
i
c
oig. 2. Antibody response of immunized mice. Serum titres of anti-BoHV-5 total Ig
ose, administered either with no adjuvant or formulated with QB-90U, Quil A or a
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as normalized using -actin as housekeeping gene. The relative
RNA amount in each sample was calculated using the 2−Ct
ethod [24] where Ct = Ctgene of interest − CtActbAct, and expressed
s  relative mRNA level in the test group compared to the non-
timulate control group.
.9.  Statistical analysis
The  data were expressed as mean ± standard error (S.E.) or stan-
ard deviation (S.D.) and examined for statistical signiﬁcance with
he Student’s t-test. P-values of less than 0.05 were considered to
e statistically signiﬁcant.
.  Results and discussion
.1.  QB-90U is signiﬁcantly less toxic than Quil A
Fig. 1a shows the haemolytic activities of QB-90U and
uil A. Their respective HD50 values were 125 ± 5 g/mL and
2 ± 2 g/mL, and their haemolytic activities at the concentrations
sed for vaccination (100 and 50 g/mL) were about 15% and 55%,
espectively. Thus, compared with Quil A, QB-90U was  only slightly
aemolytic at the concentration used for immunization. Its low
aemolytic activity allowed including QB-90U in the inoculated
reparation at a higher concentration than is possible for Quil A.A similar result was obtained in the cytotoxicity assay, which
s shown in Fig. 1b. Indeed, the toxicity of Quil A against VERO
ells was much higher than that of QB-90U. At a concentration
f 100 g/mL, more than 80% of cells were viable after incubating of IgG1, IgG2a, IgG2b (a) and IgG3 (b) isotypes, 2 weeks after the second antigen
he values are expressed as the mean value ± S.E. (n = 6) in arbitrary units (a) or OD
e group immunized with no adjuvant; and #, with the alum group (P < 0.05).
for  48 h at 37 ◦C with QB-90U, while at the same concentration of
Quil A just about 20% were viable. At 50 g/mL, the concentration
used for immunization with Quil A, a viability of approximately 30%
was observed with this saponin fraction, whereas no toxicity was
detected with QB-90U
These  results on the in vitro toxicity of QB-90U and Quil A agree
with previous reports on their in vivo toxicity in mice [11,15,17].
Taken together, they indicate that QB-90U is signiﬁcantly less toxic
than Quil A, despite being obtained from a species closely related to
Q. saponaria, and of experimental evidence of structural similarity
to Quil A [17].
3.2.  QB-90U induces the production of high titres of anti BoHV-5
IgG  containing neutralizing antibodies
The levels of anti-BoHV-5 IgG as well as IgG1, IgG2a and IgG2b
were signiﬁcantly enhanced by QB-90U, alum and Quil A, compared
with the control group (Fig. 2a). Interestingly, mice immunized
with either QB-90U or Quil A presented a similar increase of serum
IgG2a titres which were signiﬁcantly higher than those obtained
for the alum group (P < 0.05). The titres of anti-BoHV-5 IgG3 are
separately represented for clarity purposes (Fig. 2b). A signiﬁcant
increase was detected in mice immunized using QB-90U and Quil
A compared with either the control or the alum groups.
The  results in Fig. 2 show that QB-90U induces a strong antibody
response characterized by high titres of total IgG with enhanced
production of IgG1, IgG2a, IgG2b and IgG3 isotypes, with no sta-
tistical differences with the one elicited by Quil A. In terms of the
production of total IgG, IgG1 and IgG2a, these results are consistent
F. Silveira et al. / Vaccine 29 (2011) 9177– 9182 9181
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Fig. 5. Analysis of Th1 cytokine expression of immunized mice. mRNA expression
levels  of (a) IFN- and (b) IL-2 in BoHV-5-stimulated and non-stimulated spleno-
cytes  from mice immunized with the preparation of BoHV-5 using no adjuvant or
formulated with QB-90U, Quil A or alum, 120 days after the second antigen dose.
The mRNA levels relative to the one of non-stimulated splenocytes from the group
immunized with no adjuvant are presented as mean values ± S.E. (n = 3). Signiﬁcant
differences  with the group immunized with no adjuvant are indicated *(P < 0.05)ig. 3. Neutralizing antibodies in the serum of immunized mice. Serum titres of
oHV-5-neutralizing antibodies, 2 weeks after the second antigen dose, adminis-
ered  using no adjuvant or with either QB-90U, Quil A or alum as adjuvants.
ith those previously obtained when the viral antigen BoHV-1 was
o-administered with QB-90 [17]. Furthermore, they highlight dif-
erences in the isotype proﬁle of mice immunized with alum or the
aponin preparations: the IgG2a response was signiﬁcantly higher
n the QB-90U and Quil A groups than in the alum group; and only
he saponin preparations led to a signiﬁcant increase in the titres
f IgG3. In the mouse, Th1 responses are usually associated with
nhanced isotype switching to IgG2a and IgG3 (which are promoted
y INF-), whereas Th1 responses stimulate the production of IgG1
which is promoted by IL-4) [25,26]. In this context, and although
ot conclusive, the isotype pattern elicited by QB-90U – rather sim-
lar to the one obtained with Quil A – indicate that it is capable of
nducing an antibody response with a Th1-type bias, as evidenced
y the high levels of IgG2a and the production of IgG3. In addition,
he elevated titres of IgG1 suggest that Th2 CD4+ T cells are also
nvolved in the response against the administered antigen.
Fig.  3 shows the titres of neutralizing antibodies against BoHV-
 in sera from the different groups. The titres from the QB-90U or
uil A groups were more than four times higher than those from
he alum and control groups. These results point to the secretion
f elevated titres of high afﬁnity antibodies against the adminis-
ered antigen in mice immunized with the saponin preparations,
n effect that is crucial to generate protective immunity against a
iral infection.
.3.  Similar to Quil A, QB-90U induced the generation of CD4+ T
ells with a Th1 phenotype
Fig.  4 summarizes the results of the DTH assay for the different
roups of mice. A signiﬁcant response was observed in the QB-90U,
***, #
*
**
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ig. 4. Analysis of delayed type hypersensitivity (DTH) reaction of immunized mice.
he assay was  carried out 2 weeks after the second immunization of mice with the
oHV-5 preparation either with no adjuvant or formulated with QB-90U, Quil A or
lum. Mice injected only with saline solution (no antigen) were also used as a control
roup (Saline). The DTH response is expressed as the mean value ± S.D. (n = 3); sig-
iﬁcant differences are indicated: *(P < 0.01), **(P < 0.001) and ***(P < 0.0001), with
he group immunized with no adjuvant; #(P < 0.001) with the alum group.and **(P < 0.01).
Quil A and alum groups (P < 0.0001, P < 0.001 and P < 0.01, respec-
tively) albeit in the latter case the response was milder. Actually,
the DTH response of mice immunized with QB-90U was  also sig-
niﬁcantly higher than the one of the alum group (P < 0.01). Taking
into account that a positive DTH reaction is attributed to memory
Th1 CD4+ T cells [27], these results indicate that, similar to Quil A
[28], QB-90U is capable of stimulating the generation of Th1 cells
against the administered antigen.
The response elicited by QB-90U, speciﬁcally the proﬁle of IgG
subclasses and the positive DTH reaction, led us to analyze the
expression of Th1 cytokines to conﬁrm the capacity of this saponin
preparation to induce the differentiation of T cells with a Th1 phe-
notype. Fig. 5 shows the relative expression levels of IFN- and
IL-2, in antigen-stimulated and non-stimulated splenocytes, 120
days after the second immunization. Higher levels of IFN- and IL-2
mRNA relative to the control group were observed in mice from the
QB-90U and Quil A groups. In the case of IFN-, the differences were
statistically signiﬁcant in non-stimulated splenocytes from mice of
the QB-90U group (P < 0.05) and in antigen stimulated splenocytes
from animals immunized with Quil A (P < 0.05). In the case of IL-2,
signiﬁcant differences were observed in all assayed samples, that is,
in antigen stimulated and non-stimulated splenocytes from mice of
the QB-90U (P < 0.01 and P < 0.05, respectively) and Quil A (P < 0.01
and P < 0.05, respectively) groups. As somehow expected, no signif-
icant differences were detected in the expression of IFN- or IL-2
in mice from the alum group.
The  expression pattern of Th1 cytokines in mice from the QB-
90U group – very  similar to the one of the Quil A group and
markedly different from the alum group – showed that this saponin
9 cine 2
f
c
4
f
w
i
f
t
p
w
a
r
t
T
t
h
a
s
A
d
t
D
r
a
g
N
C
(
P
(
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[27] Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-
type hypersensitivity is mediated by TH1 clones. J Immunol 1987;138(June182 F. Silveira et al. / Vac
raction from Q. brasiliensis did promote the generation of CD4+ T
ells with a Th1 phenotype.
.  Conclusion
Considered globally, our results show that the saponin fraction
rom Q. brasiliensis that we named QB-90U is a safe preparation
hose adjuvant effect resembles the one of Quil A, when used for
mmunization with a viral antigen (BoHV-5). Indeed, both saponin
ractions stimulated the production of high antibody titres, con-
aining neutralizing antibodies, and a strong DTH response. Similar
atterns of IgG subclasses were observed in immunized mice,
hich suggested the involvement of Th2 (high IgG1 levels) as well
s Th1 (high IgG2a and IgG3 levels) CD4+ cells in the antibody
esponse; the participation of the latter was speciﬁcally conﬁrmed
hrough the detection of increased expression of IL-2 and INF-.
he low in vitro (this work) and in vivo (our previous study [17])
oxicity of QB-90U and its high effectiveness to generate strong
umoral and cellular responses towards a co-administered viral
ntigen allow us to propose that this saponin fraction can be con-
idered as an interesting alternative to Quil A adjuvants.
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